Global Community

Imerys is leaning into electric-vehicle batteries and greener building materials, hoping new projects and premium products can lift profits even if traditional markets stay sluggish. The big question is whether its flagship lithium push can arrive on time and at a sensible cost, or whether delays, low lithium prices, and legal overhangs keep returns under pressure.Read more

Fusion Finance is trying to grow beyond microloans by building a secured small-business lending arm and pushing more of its work onto digital tools, which could make its earnings steadier over time. But the story depends on rural cash flows holding up, funding staying available, and its new credit models and cost savings working as planned.Read more

Hackett Group is trying to shift from selling hours of consulting to selling AI-powered tools and packaged know-how, aiming for steadier, higher-quality profits. The upside is real if customers adopt these new offerings quickly, but early results show disruption and execution risk as the business changes shape.Read more

HCL Technologies is leaning hard into the build-out of AI-focused data centers and “AI factory” projects, aiming to win bigger, stickier work from major tech partners. The key question is whether these new AI deals and in-house tools can lift growth beyond what the market seems to expect—or if today’s price already reflects the upside.Read more

SEB’s push into professional coffee services and fast-growing home appliance categories could help it bounce back as demand improves and costs get spread across a bigger sales base. But the story depends on smoother trade and currency conditions—and the company’s debt and spending plans leave less room for error if markets soften.Read more

Great-West Lifeco leans into retirement and wealth services, aiming to earn more from fees and less from capital-heavy insurance, as more people need help saving for life after work. The upside depends on Empower turning more retirement savers into long-term wealth customers, while competition and shifting market conditions could make that harder than it looks.Read more

Mayne Pharma is leaning into women’s health and branded dermatology as changing prescriptions and insurance coverage make it easier for patients to get its products. The bigger question is whether those tailwinds can turn into real profit as competition, rising costs, and one-off charges threaten to hold earnings back.Read more

Penumbra could get a long runway if more hospitals adopt its catheter tools to remove dangerous blood clots in the lungs and legs, especially as doctors gain confidence from recent study results. The upside hinges on new product rollouts and wider use around the world, but slower hospital uptake or safety and approval setbacks could cool the story.Read more

Oatly pushes into more markets with new oat-based drinks aimed at younger, health-focused shoppers, and it’s cutting costs and making more products locally to lift profits over time. But weak demand in North America and uncertainty around its China business could keep growth and profits under pressure.Read more